Results 21 to 30 of about 999,068 (357)

IFITM3 Interacts with the HBV/HDV Receptor NTCP and Modulates Virus Entry and Infection

Viruses, 2022
The Na+/taurocholate co-transporting polypeptide (NTCP, gene symbol SLC10A1) is both a physiological bile acid transporter and the high-affinity hepatic receptor for the hepatitis B and D viruses (HBV/HDV).
Massimo Palatini, Simon Franz Müller, Michael Kirstgen, Silke Leiting, Felix Lehmann, Lena Soppa, Nora Goldmann, Christin Müller, Kira Alessandra Alicia Theresa Lowjaga, Jörg Alber, Giuliano Ciarimboli, John Ziebuhr, Dieter Glebe, Joachim Geyer   +13 more
doaj   +1 more source

Chronic hepatitis B [PDF]

Hepatology, 2001

Lok, Anna Suk-Fong, McMahon, Brian J.
openaire   +5 more sources

Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors

Viruses, 2021
Identification of Na+/taurocholate co-transporting polypeptide (NTCP) as high-affinity hepatic entry receptor for the Hepatitis B and D viruses (HBV/HDV) opened the field for target-based development of cell-entry inhibitors. However, most of the HBV/HDV
Michael Kirstgen, Kira Alessandra Alicia Theresa Lowjaga, Simon Franz Müller, Nora Goldmann, Felix Lehmann, Dieter Glebe, Karl-Heinz Baringhaus, Joachim Geyer   +7 more
doaj   +1 more source

Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-Naïve chronic HBV patients [PDF]

, 2013
Background: Immunomodulators and Nucleotide analogues have been used globally for the dealing of chronic hepatitis B virus (HBV) infection. However, the development of drug resistance is a major limitation to their long-term effectiveness.
Abedi, F., Alavian, S.M., Ataei, B., Azad, T.M., Daram, M., Fazeli, Z., Ghamari, S., Goodarzi, Z., Jazayeri, S.M., Judaki, M.A., Kalantari, E., Karimzadeh, H., Keyvani, H., Khedive, A., Mahabadi, M., Mahmoodi, M., Malekzadeh, R., Mansour-Ghanaei, F., Montazeri, G., Moradi, A., Nejatizadeh, A., Norouzi, M., Pourhosseingholi, M.A., Rafatpanah, H., Ramezani, F., Saberfar, E., Saberfiroozi, M., Samimirad, K., Sanei-Moghaddam, I., Sarizadeh, G., Sayad, B., Somi, M.H., Yaran, M., Ziee, M.   +33 more
core   +1 more source

Efficacy of Birth Dose Vaccination in Preventing Mother-to-Child Transmission of Hepatitis B: A Randomized Controlled Trial Comparing Engerix-B and Sci-B-Vac

Vaccines, 2021
Background and aims: Peripartum transmission of hepatitis B virus (HBV) from an infected mother to the child can be prevented in most but not all cases by immediate vaccination of the newborn.
Rifaat Safadi, Tawfik Khoury, Nizar Saed, Marwan Hakim, Jeryes Jamalia, Yousef Nijim, Nicola Farah, Tawfik Nuser, Nidaa Natur, Mahmud Mahamid, Johnny Amer, Pia L. Roppert, Wolfram H. Gerlich, Dieter Glebe   +13 more
doaj   +1 more source

Association between metabolic syndrome and its individual components with viral hepatitis B [PDF]

, 2014
BACKGROUND: The association between hepatitis B and metabolic syndrome (MetS) has not been well described. Overall epidemiologic evidences for this association have suggested conflicting results.
Jinjuvadia, Raxitkumar, Liangpunsakul, Suthat   +1 more
core   +1 more source

Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now [PDF]

, 2015
Despite of the progress made in vaccine and antiviral therapy development, hepatitis B virus (HBV) infection remains a major health care problem. More than 240 million people are chronically infected worldwide showing differences in the severity of liver
Cuestas, María Luján, Eguibar, Nair, Gonzalez, Rodrigo Horacio, Nusblat, Alejandro David, Perazzo, Priscila   +4 more
core   +1 more source

Barriers to accessing hepatitis B medication: a qualitative study from the USA and Canada

BMJ Open
Objectives To collect and document the numerous barriers that people living with hepatitis B (PLHB) encounter when trying to access their hepatitis B virus (HBV) medications.Design Researchers collected qualitative data through 24 online interviews.
Sophie Jacob, Michaela Jackson, Yasmin Ibrahim, Catherine Freeland, Beatrice Zovich, Chari Cohen   +5 more
doaj   +1 more source

Best practices for engaging with affected communities: chronic hepatitis B as a case study

Infectious Diseases of Poverty
Hepatitis B is the single most common cause of liver cancer, affecting > 250 million people worldwide (mostly in resource limited communities) and killing > 1 million people annually. The condition is marked by poor rates of diagnosis (14%) and treatment
Thomas Tu, Nafisa Yussf, Lien Tran, Kim Ngo, Su Wang, Adi Mondel, Isabelle Purcell, Jacki Chen, Wendy Lo, Bright Ansah, Kenneth Kabagambe, Soumen Basu, Dee Lee, Supa Chantschool, Chris Munoz, Ivana Dragojevic, Marko Korenjak, Fiona Borondy-Jenkins, Yasmin Ibrahim, Beatrice Zovich, Chari Cohen   +20 more
doaj   +1 more source

The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: A population-based study [PDF]

, 2009
Background: Hepatitis B virus infection is a very common cause of chronic liver disease worldwide. It is estimated that 3 of Iranians are chronically infected with hepatitis B virus.
Abolghasemi, H., Amini-Kafiabad, S., Assari, S., Hosseini, M.R., Jamali, J., Maghsudlu, M., Malekzadeh, R., Merat, S., Nouraie, M., Pourshams, A., Radmard, A.R., Rezvan, H., Zaer-Rezaii, H., Zeid-Abadi-Nejhad, M.   +13 more
core